Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer.

about

Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer.

Item

http://www.wikidata.org/entity/Q36211461

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Five years of stable disease w ...... with metastatic breast cancer.

@ast

Five years of stable disease w ...... with metastatic breast cancer.

@en

type

Item

label

Five years of stable disease w ...... with metastatic breast cancer.

@ast

Five years of stable disease w ...... with metastatic breast cancer.

@en

prefLabel

Five years of stable disease w ...... with metastatic breast cancer.

@ast

Five years of stable disease w ...... with metastatic breast cancer.

@en

P1476

Five years of stable disease w ...... with metastatic breast cancer

@en

P2093

Armando Perrella

http://www.w3.org/2001/XMLSchema#string

Franco Roviello

http://www.w3.org/2001/XMLSchema#string

Giandomenico Roviello

http://www.w3.org/2001/XMLSchema#string

Letizia Laera

http://www.w3.org/2001/XMLSchema#string

Roberto Petrioli

http://www.w3.org/2001/XMLSchema#string

P2860

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.

Rapid vascular regrowth in tumors after reversal of VEGF inhibition.

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials.

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.

P304

493-497

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1080/15384047.2015.1017692

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Daniele Marrelli

E Francini

Maria Antonietta Mazzei

Susanna Guerrini

P577

2015-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25719413

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

4622062

http://www.w3.org/2001/XMLSchema#string